Format

Send to

Choose Destination
Curr Med Res Opin. 2012 Jan;28(1):23-5. doi: 10.1185/03007995.2011.628651. Epub 2011 Nov 21.

Industry funded clinical trials: bias and quality.

Author information

1
angelodelp@gmail.com

Abstract

The quality of the clinical data supporting the development and ultimately the approval for medical use of new drugs is often challenged. Many share the perception that the business goals of the pharmaceutical industry overrule the best scientific efforts to accrue critical knowledge on a new molecule, in order to inform investment of resources, regulatory approvals and appropriate use by patients. Despite this common belief, few scientists have attempted to assess objectively the quality of industry funded (IF) clinical trials by measuring it and comparing it with non-industry funded (NIF) clinical trials in a data-driven fashion. Overall, the average quality of IF clinical research has been reported to be higher than the quality of NIF clinical research.

PMID:
22103762
DOI:
10.1185/03007995.2011.628651
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center